MEDICINE: New Reimbursement Mechanism May Serve as Model for Other Hospitals
A recent deal between Tri-City Medical Center and San Diego County could serve as a new model in funding mental health at hospitals, one potential solution to a strained psychiatric system.
Executive search firm Bench International has taken up residence in the San Diego incubator space run by BioLabs.
Biotech’s Brain Cancer Treatment Posts Disappointing Results
In 2017, Tocagen raised $87 million in a public offering. Investors saw potential in the San Diego biotech’s combo treatment for recurrent brain cancer.
Data Committee Finds ‘High Level of Treatment Success’
Amplx Pharmaceuticals recently revealed promising data for a drug designed to treat life-threatening infections.
San Diego-based Metacrine has inked a loan and security agreement for up to $50 million with K2 HealthVentures.
Boundless Bio Inc. emerged Sept. 19 with $46.4 million in funding and a claim to new territory: extrachromosomal DNA
Acadia Pharmaceuticals is planning to raise $250 million through a public stock offering.
HEALTH: Consumer Focus on Nutrition Drives Demand
More and more, San Diego-based food companies are placing focus on including functional ingredients in their “better for you” offerings.
DelMar Pharmaceuticals has relocated from British Columbia to San Diego.
San Diego’s SGI-DNA, a spinout of Synthetic Genomics, has raised a $25 million series A round.
MEDICINE: DermTech’s Patch May Change Skin Cancer Diagnostics
Could that suspicious mole be cancerous? DermTech wants doctors to reach for a patch, not a scalpel.
Obalon Therapeutics Inc. announced Dr. Helmuth Billy as medical director for its first company-owned weight-loss treatment center.
BIOTECH: Cancer Drug Developer Plans To Build Its Pipeline
After raising $175.2 million in an initial public offering this spring, Turning Point Therapeutics has returned to the public market.
Shares of Tocagen fell Sept. 12 after its brain cancer therapy failed a late-stage clinical trial.
The cancer drug developer on Sept. 10 raised $202.5 million in a follow-on offering. Turning Point sold 4.5 million shares of common stock at a price of $45 a share.